Titre :
|
Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. (1998)
|
Auteurs :
|
M. KRAHN ;
A.S. DETSKY ;
R. GUASPARINI ;
M. SHERMAN
|
Type de document :
|
Article
|
Dans :
|
American journal of public health (vol. 88, n° 11, 1998)
|
Pagination :
|
1638-1644
|
Langues:
|
Anglais
|
Mots-clés :
|
Hépatite virale B
;
Virose
;
Infection
;
Prévention santé
;
Vaccination
;
Programme élargi vaccination
;
Programme santé
;
Analyse coût efficacité
;
Economie santé
;
Enfant
;
Homme
;
Enfant 6 9 ans
;
Appareil digestif [pathologie]
;
Foie [pathologie]
|
Résumé :
|
[BDSP. Notice produite par INIST R0xm3Nos. Diffusion soumise à autorisation]. Objectives. This study evaluated the costs and cost-effectiveness of a shcool-based grade 6 universal vaccination program against hepatitis B. Methods. We performed a descriptive cost study and cost-effectiveness analysis of British Columbia's vaccination program for 1994 and 1995. Since 1992, public health nurses have administered hepatitis B vaccine to grade 6 students in shcools. We measured costs of vaccine, vaccine administration, and net program costs and used a validated Markov model to calculate the cost-effectiveness of the program. Results. Vaccinating each student cost $44, $24 of which was the cost of vaccine administration. The net cost was $9 per person ; considering productivity costs, net savings were $75 per person. Marginal cost per life year gained was $2100. Universal adolescent vaccination is also economically attractive in regions with incidence rates below 3 cases per 100 00 per year. Conclusions. Hepatitis B vaccine can be delivered in North American schools at a reasonable cost. Adolscent veccination is economically attractive in North American regions of high and average incidence rates. Our analysis supports vaccination in adolescents who remain at risk for hepatitis B virus infection.
|